ACON heads into its Q1 results — just reported after the close on May 13 — with a striking contrast: management buying stock with both hands while short sellers have been aggressively rebuilding positions over the past six weeks.
The insider signal is unusually clustered. CEO Brent Ness bought 6,289 shares at $3.18 on May 11, spending just over $20,000. A director added another 5,664 shares the following day. Director David K. Neal picked up 2,500 shares at $3.10 earlier in the week, and director William Wesemann bought 1,562 shares on May 6. Four separate insiders buying in less than a week is notable for a company this size. Net insider purchases over the past 90 days total 16,015 shares, worth roughly $51,000 — small in dollar terms but meaningful as a signal of internal confidence at current levels.
Short sellers have reached a different conclusion. Short interest as a percentage of free float has more than doubled since early April, climbing from roughly 4.6% on April 1 to 10.2% today. The raw share count tells the same story: from around 100,000 shares short to 225,000 in six weeks. The ORTEX short score has tracked the build, running at 72.3 out of 100 — a level that places ACON firmly in the more-shorted end of its peer group. The borrow market has tightened somewhat in step: cost to borrow is running around 20.3% annualised, down from a peak near 40% in early April but well above frictionless territory. Availability has eased back slightly from mid-April highs, with the lending pool roughly half-utilised at current levels — not a squeeze environment, but not a loose borrow either.
The Street picture is thin and somewhat stale. Ascendiant Capital's Lucas Ward, the lone analyst on the name, lowered his price target sharply to $7.00 from $23.00 in late March — a cut of more than two-thirds — while maintaining a Buy rating. The target remains at $7.00 against a current price of $3.15, implying substantial paper upside. That gap deserves caution: the target was set nearly seven weeks ago and may not fully reflect the company's current revenue run rate. The bear case centres on slow commercial adoption, a thin single-source revenue stream from Nociscan reports, and high operating costs relative to income. Bulls point to a $22 million cash position, an expanding CLARITY trial network — Lanman Spinal Neurosurgery was added as a clinical site on May 7 and a first Los Angeles private-practice site joined on May 8 — and a US spine market opportunity estimated above $400 million annually.
The earnings print just released tells its own story. Q1 EPS came in at a loss of $1.34, beating the $1.55 estimate, though revenue of $21,140 missed the $25,000 consensus. The recent earnings history shows wide dispersion: the February 2026 print produced a 6.7% next-day gain and a 22% five-day rally, while the November 2025 announcement triggered a 13.9% single-day drop. That volatility range underlines how binary each event has been for this stock.
The setup into any post-earnings reaction now combines a short base that has grown significantly since April, a cluster of insider buys at current prices, and a trial expansion news flow that management has been active in releasing. The key question in coming sessions is whether the EPS beat offsets the revenue miss — and whether the CLARITY trial enrollment updates, expected as the year progresses, shift the argument for or against the bears who have been pressing the position all spring.
See the live data behind this article on ORTEX.
Open ACON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
